ECSP088532A - Formulación de suspensión de fexofenadina - Google Patents

Formulación de suspensión de fexofenadina

Info

Publication number
ECSP088532A
ECSP088532A EC2008008532A ECSP088532A ECSP088532A EC SP088532 A ECSP088532 A EC SP088532A EC 2008008532 A EC2008008532 A EC 2008008532A EC SP088532 A ECSP088532 A EC SP088532A EC SP088532 A ECSP088532 A EC SP088532A
Authority
EC
Ecuador
Prior art keywords
suspension formulation
fexofenadine
fexofenadine suspension
dihydrate
directed
Prior art date
Application number
EC2008008532A
Other languages
English (en)
Spanish (es)
Inventor
Vinh D Tran
Prafulla Agrawala
Kazimiers Chrzan
Rajiv Haribhakti
Matthew Mermey
Curtis J Porcello
Gary Lee Silvey
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088532(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of ECSP088532A publication Critical patent/ECSP088532A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
EC2008008532A 2005-12-14 2008-06-12 Formulación de suspensión de fexofenadina ECSP088532A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14

Publications (1)

Publication Number Publication Date
ECSP088532A true ECSP088532A (es) 2008-08-29

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008532A ECSP088532A (es) 2005-12-14 2008-06-12 Formulación de suspensión de fexofenadina

Country Status (38)

Country Link
US (1) US8933097B2 (https=)
EP (1) EP1965768B1 (https=)
JP (1) JP5308824B2 (https=)
KR (1) KR101452792B1 (https=)
CN (1) CN101316580B (https=)
AR (1) AR058323A1 (https=)
AT (1) ATE431137T1 (https=)
AU (1) AU2006326551B2 (https=)
BR (1) BRPI0619895B1 (https=)
CA (1) CA2633086C (https=)
CR (1) CR9993A (https=)
CY (1) CY1109320T1 (https=)
DE (1) DE602006006870D1 (https=)
DK (1) DK1965768T3 (https=)
DO (1) DOP2006000274A (https=)
EC (1) ECSP088532A (https=)
EG (1) EG25866A (https=)
ES (1) ES2327168T3 (https=)
HN (1) HN2008000875A (https=)
HR (1) HRP20090411T1 (https=)
IL (1) IL192067A (https=)
JO (1) JO2549B1 (https=)
MA (1) MA30152B1 (https=)
MY (1) MY146988A (https=)
NO (1) NO339877B1 (https=)
NZ (1) NZ568943A (https=)
PE (1) PE20071003A1 (https=)
PL (1) PL1965768T3 (https=)
PT (1) PT1965768E (https=)
RS (1) RS51135B (https=)
RU (1) RU2405538C2 (https=)
SI (1) SI1965768T1 (https=)
TN (1) TNSN08186A1 (https=)
TW (1) TWI377061B (https=)
UA (1) UA89584C2 (https=)
UY (1) UY30021A1 (https=)
WO (1) WO2007070517A2 (https=)
ZA (1) ZA200803985B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
BR112015032791A2 (pt) * 2013-07-03 2017-07-25 Scherer Technologies Llc R P composição para uso como enchimento de cápsula, e, cápsula
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
EP4199980A1 (en) * 2020-08-18 2023-06-28 Innate S.r.l. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
AU2021480621A1 (en) * 2021-12-29 2024-07-18 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
EP4651852A1 (en) 2023-01-20 2025-11-26 Opella Healthcare Group SAS Paraben-free fexofenadine formulations
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
CA2514570C (en) * 2003-01-30 2011-09-06 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
CN101228128A (zh) 2005-07-27 2008-07-23 桑多斯股份公司 一种用于制备取代苯基醚化合物和罗西格列酮的方法
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Also Published As

Publication number Publication date
PT1965768E (pt) 2009-08-07
PE20071003A1 (es) 2007-10-03
DK1965768T3 (da) 2009-09-07
WO2007070517A2 (en) 2007-06-21
UY30021A1 (es) 2007-07-31
DOP2006000274A (es) 2007-10-15
JP5308824B2 (ja) 2013-10-09
JP2009519935A (ja) 2009-05-21
HN2008000875A (es) 2012-01-30
UA89584C2 (en) 2010-02-10
TW200812581A (en) 2008-03-16
IL192067A0 (en) 2009-02-11
DE602006006870D1 (de) 2009-06-25
NZ568943A (en) 2010-04-30
KR101452792B1 (ko) 2014-10-22
US20080299211A1 (en) 2008-12-04
CA2633086A1 (en) 2007-06-21
ES2327168T3 (es) 2009-10-26
ATE431137T1 (de) 2009-05-15
MY146988A (en) 2012-10-15
RU2405538C2 (ru) 2010-12-10
BRPI0619895B1 (pt) 2022-04-12
SI1965768T1 (sl) 2009-10-31
WO2007070517A3 (en) 2007-08-23
TNSN08186A1 (en) 2009-10-30
CA2633086C (en) 2011-10-18
CN101316580B (zh) 2011-11-16
ZA200803985B (en) 2009-03-25
CN101316580A (zh) 2008-12-03
RS51135B (sr) 2010-10-31
TWI377061B (en) 2012-11-21
IL192067A (en) 2010-12-30
CY1109320T1 (el) 2014-07-02
JO2549B1 (en) 2010-09-05
AU2006326551B2 (en) 2012-06-07
CR9993A (es) 2008-09-23
EP1965768A2 (en) 2008-09-10
KR20080074180A (ko) 2008-08-12
US8933097B2 (en) 2015-01-13
RU2008128418A (ru) 2010-01-20
BRPI0619895A2 (pt) 2011-10-25
NO20082904L (no) 2008-09-10
AR058323A1 (es) 2008-01-30
HK1123197A1 (en) 2009-06-12
MA30152B1 (fr) 2009-01-02
HRP20090411T1 (hr) 2010-01-31
PL1965768T3 (pl) 2009-11-30
EG25866A (en) 2012-09-12
AU2006326551A1 (en) 2007-06-21
EP1965768B1 (en) 2009-05-13
NO339877B1 (no) 2017-02-13

Similar Documents

Publication Publication Date Title
ECSP088532A (es) Formulación de suspensión de fexofenadina
IL260293A (en) Azeotrope-like compositions of cis-1,1,1,4,4,4-hexafluoro-2-butene
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
UA105229C2 (uk) Фармацевтичний склад
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
BRPI0911126A2 (pt) Formulação aquosa estável contendo esporo
BRPI1015996A8 (pt) composições farmacêuticas aquosas contendo complexos de borato-poliol
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
SG161311A1 (en) Novel use of spiegelmers
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
AR093716A1 (es) Composicion de cuidado oral
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
CY1116840T1 (el) Χρηση 24-norudca
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
CY1118585T1 (el) Ενωση βενζοθειαζολονης
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
AR077915A1 (es) Forma cristalina de pemirolast
ECSP088374A (es) Formulacion de aerosol para inhalacion
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη